Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Publication Date timeline is not available.
Page 1
Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial.
Diabetol Metab Syndr. 2017 May 15;9:35. doi: 10.1186/s13098-017-0232-2. eCollection 2017.
Diabetol Metab Syndr. 2017.
PMID: 28515791
Free PMC article.
Improved glycaemic variability and time in range with dapagliflozin versus gliclazide modified release among adults with type 2 diabetes, evaluated by continuous glucose monitoring: A 12-week randomized controlled trial.
Vianna AGD, Lacerda CS, Pechmann LM, Polesel MG, Marino EC, Scharf M, Detsch JM, Marques K, Sanches CP.
Vianna AGD, et al. Among authors: polesel mg.
Diabetes Obes Metab. 2020 Apr;22(4):501-511. doi: 10.1111/dom.13913. Epub 2019 Dec 3.
Diabetes Obes Metab. 2020.
PMID: 31709738
Clinical Trial.
Item in Clipboard
A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes.
Vianna AGD, Lacerda CS, Pechmann LM, Polesel MG, Marino EC, Faria-Neto JR.
Vianna AGD, et al. Among authors: polesel mg.
Diabetes Res Clin Pract. 2018 May;139:357-365. doi: 10.1016/j.diabres.2018.03.035. Epub 2018 Mar 26.
Diabetes Res Clin Pract. 2018.
PMID: 29596951
Clinical Trial.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.